ERYTHROMYCIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Erythromycin, and what generic alternatives are available?
Erythromycin is a drug marketed by Azurity, Barr, Encube, Fougera Pharms, Padagis Us, Elkins Sinn, Bausch And Lomb, Pharmaderm, Pharmafair, Sentiss, Paddock Llc, Alpharma Us Pharms, Bausch, Lilly, Pai Holdings Pharm, Pharmobedient Cnsltg, Renaissance Pharma, Epic Pharma Llc, Norvium Bioscience, Amneal Pharms Co, Torrent, Alembic, Alkem Labs Ltd, Cadila Pharms Ltd, Teva Pharms Usa Inc, Zydus Lifesciences, Zydus Pharms, Lyne, Ivax Sub Teva Pharms, Watson Labs, Cosette, Life Labs, Amneal Pharms, Ani Pharms, Endo Operations, Dista, Naska, Parke Davis, Aurobindo Pharma Usa, Abraxis Pharm, Baxter Hlthcare, Exela Pharma, Nexus, Teva Parenteral, Lederle, and Purepac Pharm. and is included in seventy-six NDAs.
The generic ingredient in ERYTHROMYCIN is erythromycin stearate. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin stearate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERYTHROMYCIN?
- What are the global sales for ERYTHROMYCIN?
- What is Average Wholesale Price for ERYTHROMYCIN?
Summary for ERYTHROMYCIN
| US Patents: | 0 |
| Applicants: | 46 |
| NDAs: | 76 |
| Finished Product Suppliers / Packagers: | 31 |
| Raw Ingredient (Bulk) Api Vendors: | 103 |
| Clinical Trials: | 136 |
| Patent Applications: | 5,334 |
| Drug Prices: | Drug price information for ERYTHROMYCIN |
| Drug Sales Revenues: | Drug sales revenues for ERYTHROMYCIN |
| What excipients (inactive ingredients) are in ERYTHROMYCIN? | ERYTHROMYCIN excipients list |
| DailyMed Link: | ERYTHROMYCIN at DailyMed |
See drug prices for ERYTHROMYCIN
Recent Clinical Trials for ERYTHROMYCIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Takeda | Phase 1 |
| Chang Gung Memorial Hospital | Phase 1/Phase 2 |
| Assiut University | N/A |
Pharmacology for ERYTHROMYCIN
| Drug Class | Macrolide Antimicrobial Macrolide |
| Physiological Effect | Decreased Sebaceous Gland Activity |
Medical Subject Heading (MeSH) Categories for ERYTHROMYCIN
Anatomical Therapeutic Chemical (ATC) Classes for ERYTHROMYCIN
US Patents and Regulatory Information for ERYTHROMYCIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cadila Pharms Ltd | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | GRANULE;ORAL | 216212-001 | Nov 21, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lederle | ERYTHROMYCIN STEARATE | erythromycin stearate | TABLET;ORAL | 062089-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alkem Labs Ltd | ERYTHROMYCIN | erythromycin | TABLET;ORAL | 216066-002 | Jul 13, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Amneal Pharms Co | ERYTHROMYCIN | erythromycin | TABLET, DELAYED RELEASE;ORAL | 210954-001 | Jul 2, 2019 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Azurity | ERYTHROMYCIN ETHYLSUCCINATE | erythromycin ethylsuccinate | TABLET;ORAL | 061904-001 | Approved Prior to Jan 1, 1982 | BX | RX | No | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms Usa Inc | ERYTHROMYCIN | erythromycin | TABLET;ORAL | 214549-002 | Feb 11, 2021 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Ivax Sub Teva Pharms | ERYTHROMYCIN ESTOLATE | erythromycin estolate | CAPSULE;ORAL | 062237-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
